trial
as of 2026-07-01Bioavailability of LY03004 and Risperdal® Consta®
NCTId NCT02091388
at a glance
Phase 1 · Completed
Enrollment 108 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2015-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
108 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2014-09
Primary completion
2015-01
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Investigators
1
Simon LiStudy Chair
Sites
10 total
Little Rock, United StatesLong Beach, United StatesOrange, United StatesWashington D.C., United StatesLeesburg, United StatesAtlanta, United StatesRockville, United StatesMarlton, United StatesPhiladelphia, United StatesAustin, United States
Facts & assertions
4 sourced
Enrollment
108
Phase
PHASE1
Primary Completion Date
2015-01
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
investigator
person